SCHEMBL2260901

SCHEMBL2260901

NC(=O)Cc1cnc2ccc(Cl)cn12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.56
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
EIF2AK4 Q9P2K8 9/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KLKB1 P03952 1/20 0.38
NR1I2 O75469 1/20 0.38
ABCB11 O95342 1/20 0.38
ALB P02768 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
TSPO P30536 1/20 0.38
ADORA1 P30542 1/20 0.38
OPRM1 P35372 1/20 0.38
DRD3 P35462 1/20 0.38
OPRK1 P41145 1/20 0.38
PDE4D Q08499 1/20 0.38
KCNH2 Q12809 1/20 0.38
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260330 0.82 ADORA2A (0.41) PRMT5WDR77GABRB2
SCHEMBL2262019 0.79 KDM4E (0.39) POLBGAA
SCHEMBL2264081 0.78 PRMT5 (0.40) POLBMEN1PRMT5WDR77
SCHEMBL2259799 0.78 POLB (0.37) POLB
SCHEMBL5768245 0.78 EIF2AK4 (0.47) EIF2AK4KMT2A
SCHEMBL5767283 0.78 KDR (0.48) ALDH1A1GAAPDE4DPRMT5WDR77
SCHEMBL3607747 0.76 POLB (0.50) POLB
SCHEMBL21863408 0.76 POLB (0.69) POLBALDH1A1GAAMEN1KMT2A
SCHEMBL633944 0.75 GGPS1 (0.57) POLBALDH1A1GAAADORA3DRD3
SCHEMBL2259953 0.74 TBXAS1 (0.39) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-12-01 US disclosed
US-8022065-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-08-25 US disclosed
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY 2009-04-23 US disclosed
EP-1483265-B1 PURINE DERIVATIVES AS KINASE INHIBITORS LILLY CO ELI (US) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 POLB 1053/4885ALDH1A1 1688/4885GAA 2654/4885
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 POLB 1053/4885ALDH1A1 1688/4885GAA 2654/4885
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 POLB 1053/4885ALDH1A1 1688/4885GAA 2654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.